{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:32:40Z","timestamp":1790688760730,"version":"4.1.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T00:00:00Z","timestamp":1600732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Research Foundation of South Africa","award":["119078"],"award-info":[{"award-number":["119078"]}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["212265\/Z\/18\/Z"],"award-info":[{"award-number":["212265\/Z\/18\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wellcome Centre for Infectious Diseases Research in Africa","award":["203135\/Z\/16\/Z"],"award-info":[{"award-number":["203135\/Z\/16\/Z"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dolutegravir is associated with more weight gain than efavirenz. Loss-of-function polymorphisms in CYP2B6 result in higher efavirenz concentrations, which we hypothesized would impair weight gain among people living with human immunodeficiency virus (HIV; PLWH) starting efavirenz-based antiretroviral therapy (ART).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We studied ART-naive participants from the ADVANCE study randomized to the efavirenz \/emtricitabine\/tenofovir disoproxil fumarate (TDF) and dolutegravir\/emtricitabine\/TDF arms. We compared changes in weight and regional fat on DXA from baseline to week 48 between CYP2B6 metabolizer genotypes in the efavirenz arm, and with the dolutegravir arm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 342 participants in the dolutegravir arm and 168 in the efavirenz arm who consented to genotyping. Baseline characteristics were similar. Weight gain was greater in women than men. In the efavirenz arm CYP2B6 metaboliser genotype was associated with weight gain (P\u2005=\u2005.009), with extensive metabolizers gaining the most weight, and with changes in regional fat in women, but not in men. Weight gain was similar in CYP2B6 extensive metabolizers in the efavirenz arm and in the dolutegravir arm (P\u2005=\u2005.836). The following variables were independently associated with weight gain in all participants: baseline CD4 count, baseline human immunodeficiency virus type 1 (HIV-1) RNA, and CYP2B6 metaboliser genotype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CYP2B6 metaboliser genotype was associated with weight gain in PLWH starting efavirenz-based ART. Weight gain was similar between CYP2B6 extensive metabolizers in the efavirenz arm and in the dolutegravir arm, suggesting that impaired weight gain among CYP2B6 slow or intermediate metabolizers could explain the increased weight gain on dolutegravir compared with efavirenz observed in ADVANCE and other studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaa1073","type":"journal-article","created":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T07:09:38Z","timestamp":1595660978000},"page":"e3902-e3909","source":"Crossref","is-referenced-by-count":78,"title":["<i>CYP2B6<\/i>\n                    Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz"],"prefix":"10.1093","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3633-2878","authenticated-orcid":false,"given":"Rulan","family":"Griesel","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"},{"name":"Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3080-6606","authenticated-orcid":false,"given":"Gary","family":"Maartens","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"},{"name":"Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Chirehwa","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simiso","family":"Sokhela","sequence":"additional","affiliation":[{"name":"Ezintsha, Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godspower","family":"Akpomiemie","sequence":"additional","affiliation":[{"name":"Ezintsha, Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Moorhouse","sequence":"additional","affiliation":[{"name":"Ezintsha, Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Venter","sequence":"additional","affiliation":[{"name":"Ezintsha, Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phumla","family":"Sinxadi","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"},{"name":"Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,22]]},"reference":[{"key":"2022013110514708900_CIT0001","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","author":"Sax","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022013110514708900_CIT0002","first-page":"670","article-title":"Greater weight gain among treatment-na\u00efve persons starting integrase inhibitors","author":"Bourgi","year":"2019","journal-title":"CROI"},{"key":"2022013110514708900_CIT0003","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/cid\/ciz407","article-title":"Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy","volume":"70","author":"Bourgi","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022013110514708900_CIT0004","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2055-6640(20)30277-6","article-title":"Are new antiretroviral treatments increasing the risks of clinical obesity?","volume":"5","author":"Hill","year":"2019","journal-title":"J Virus Erad"},{"key":"2022013110514708900_CIT0005","article-title":"Risk factors for excess weight gain following switch to integrase inhibitor-based antiretroviral therapy","author":"Lake"},{"key":"2022013110514708900_CIT0006","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJMoa1904340","article-title":"Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1","volume":"381","author":"Kouanfack","year":"2019","journal-title":"N Engl J Med"},{"key":"2022013110514708900_CIT0007","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"key":"2022013110514708900_CIT0008","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S0140-6736(18)31992-5","article-title":"NCD countdown 2030: worldwide trends in non-communicable disease mortality and progress towards sustainable development goal target 3.4","volume":"392","author":"Bennet","year":"2018","journal-title":"Lancet"},{"key":"2022013110514708900_CIT0009","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1080\/17512433.2016.1221760","article-title":"Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen","volume":"9","author":"Mouton","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2022013110514708900_CIT0010","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.antiviral.2016.05.013","article-title":"Impact of elvitegravir on human adipocytes: alterations in differentiation, gene expression and release of adipokines and cytokines","volume":"132","author":"Moure","year":"2016","journal-title":"Antiviral Res"},{"key":"2022013110514708900_CIT0011","doi-asserted-by":"crossref","first-page":"e63623","DOI":"10.1371\/journal.pone.0063623","article-title":"Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction","volume":"8","author":"de Waal","year":"2013","journal-title":"PLoS One"},{"key":"2022013110514708900_CIT0012","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/FPC.0b013e32835a450b","article-title":"Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS clinical trials group protocols implicates several CYP2B6 variants","volume":"22","author":"Holzinger","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"2022013110514708900_CIT0013","first-page":"472","article-title":"Pharmacogenetics of weight gain after switch from efavirenz to integrase inhibitors","author":"Leonard","year":"2019","journal-title":"CROI)"},{"key":"2022013110514708900_CIT0014","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/oby.2011.367","article-title":"Dual-energy X-ray performs as well as clinical computed tomography for the measurement of visceral fat","volume":"20","author":"Micklesfield","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"2022013110514708900_CIT0015","volume-title":"R: a language and environment for statistical computing","author":"R Core Team.","year":"2014"},{"key":"2022013110514708900_CIT0016","volume-title":"Stata statistical software: release 16","author":"StataCorp.","year":"2019"},{"key":"2022013110514708900_CIT0017","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bcp.12590","article-title":"Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa","volume":"80","author":"Sinxadi","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2022013110514708900_CIT0018","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1089\/aid.2015.0147","article-title":"Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada","volume":"32","author":"Koethe","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2022013110514708900_CIT0019","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/hep.24459","article-title":"Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy","volume":"54","author":"Apostolova","year":"2011","journal-title":"Hepatology"},{"key":"2022013110514708900_CIT0020","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2174\/157016210793499222","article-title":"Differential effects of efavirenz and lopinavir\/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines","volume":"8","author":"Gallego-Escuredo","year":"2010","journal-title":"Curr HIV Res"},{"key":"2022013110514708900_CIT0021","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1365-2125.2009.03516.x","article-title":"A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans","volume":"68","author":"Mukonzo","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"2022013110514708900_CIT0022","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2125.2005.02536.x","article-title":"Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism","volume":"61","author":"Burger","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"2022013110514708900_CIT0023","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1128\/AAC.02532-14","article-title":"Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6","volume":"58","author":"Court","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022013110514708900_CIT0024","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1097\/QAD.0b013e328360dbb4","article-title":"Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype","volume":"27","author":"McIlleron","year":"2013","journal-title":"AIDS"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1073\/33780197\/ciaa1073.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/11\/e3902\/42339588\/ciaa1073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/11\/e3902\/42339588\/ciaa1073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T05:52:34Z","timestamp":1643608354000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/11\/e3902\/5909992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,22]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,9,22]]},"published-print":{"date-parts":[[2021,12,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1073","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2020,9,22]]}}}